In a nutshell
This study aimed to assess the usage and safety of biological treatment to treat chronic myeloid leukemia (CML). Researchers found that nilotinib (Tasigna) has a better profile as a first-line drug in the treatment of CML.
Some background
Chronic myeloid leukemia is a cancer of the bone marrow. This leads to abnormal immune cells. It is often treated with drugs that target specific proteins on cancer cells. These drugs are called tyrosine kinase inhibitors (TKIs). These drugs have considerably improved patient outcomes. It is important to research the safety of different TKIs to find the best treatment.
Methods & findings
81 patients with CML treated with TKIs were included in the study. 73 were treated with imatinib (Gleevec) for an average of 4.55 years. 8 patients received nilotinib for an average of 3.59 years.
38% of patients treated with imatinib needed to switch drugs due to side effects or poor response. No patient in the nilotinib group needed to switch. Bone and joint pain was a more common side effect in the imatinib group (68.5%) compared to the nilotinib group (25%). Other side effects reported in both groups included skin problems, diarrhea, and weakness. These were slightly more common in the imatinib group.
The bottom line
The study concluded that nilotinib was safer when compared to imatinib in the treatment of CML.
The fine print
This study focuses on safety rather than the effectiveness of the medications. More patients received imatinib than nilotinib, which might affect results. It is also a small study. Larger studies are needed to confirm the findings.
Published By :
Clinical drug investigation
Date :
Jul 24, 2018
